Clinical Study
Chemotherapy Administration during Pelvic Radiation for Cervical Cancer Patients Aged ≥ 55 Years in the SEER-Medicare Population
Table 4
Multivariate analysis for chemoradiation administration within 3 months after diagnosis in women with stages II-IVA cervical cancer from 1998 to 2002.
| Patient and tumor characteristics | number of cases () | Odds ratio* of chemoradiation | 95% Confidence interval |
| Age | | | | 55–70 years | 152 (39.5%) | 1 | — | >71 years | 233 (60.5%) | 0.62 | 0.42–0.94 |
| Stage | | | | II | 213 (55.3%) | 1 | — | III | 163 (42.3%) | 0.96 | 0.63–1.47 | IVA | 9 (2.3%) | 0.59 | 0.14–2.50 |
| Histology | | | | Squamous | 289 (75.1%) | 1 | — | Adenocarcinoma | 55 (14.3%) | 0.84 | 0.45–1.57 | Adenosquamous | 13 (3.4%) | 0.53 | 0.16–1.78 | Other | 28 (7.3%) | 0.61 | 0.26–1.43 |
| Race | | | | Caucasian | 237 (61.6%) | 1 | — | African-American | 74 (19.2%) | 1.22 | 0.72–2.06 | Other | 74 (19.2%) | 1.28 | 0.75–2.18 |
| Residence | | | | Big Metropolitan area | 235 (61.0%) | 1 | — | Metropolitan area | 94 (24.4%) | 1.48 | 0.89–2.45 | Urban, less urban, rural | 56 (14.5%) | 2.63 | 1.41–4.91 |
| Socioeconomic status, median income | | | | <30,700 | 94 (24.4%) | 1 | — | 30,701–39,425 | 93 (24.2%) | 0.77 | 0.47–1.28 | 39,426–53,707 | 102 (26.5%) | 0.72 | 0.43–1.20 | >53,708 | 96 (24.9%) | 1.18 | 0.70–1.98 |
| Comorbidity index, Charlson | | | | 0 | 274 (71.2%) | 1 | — | 1 | 63 (16.4%) | 1.09 | 0.61–1.94 | 2 | 28 (7.3%) | 0.72 | 0.31–1.65 | 3+ | 20 (5.2%) | 0.8 | 0.31–2.10 |
|
|
*Adjusted for variables listed in the tables.
|